De Wittenskip fan it Lang Libjen: Wat Wy yn 2026 Witte
August 2, 2026 · Frisian News
Longevity startups raised $4.7 billion in 2024 and 2025, yet human lifespan has not increased since the 1990s. Most breakthroughs in mice do not apply to humans, while the billionaire-funded field chases revolutionary claims instead of proven interventions.
FryskStartups op it mêd fan lang libjen hawwe yn 2024 en 2025 4,7 miljard dollar ophelle, neffens Crunchbase. De libbensferwachting yn ûntwikkele lannen is sûnt ein jierren njoggentich net omheech gien. De kleau tusken ynvestearringen en resultaten wurdt hieltyd grutter.
It jild komt út te ferwachtsjen boarnen: Bezos, Sam Altman, Peter Thiel. Risikokapitaal folget. It ferhaal is ferliedlik. Ien bedriuw, Altos Labs, helle 3 miljard dollar op mei de teory dat it herprogrammearjen fan sellen ferâldering ûngedien meitsje kin. In oar, Calico, hat sûnt 2013 1,5 miljard dollar útjûn sûnder in goedkard medisyn op 'e merk. Dochs giet de hype troch, nettsjinsteande de resultaten.
De wittenskip sels is beskiedener. De measte befinen by mûzen wurde net werhelle by minsken. Kaloribeheining ferlinget it libben fan knisters, mar lit gjin dúdlik nut foar minsken sjen yn grutte ûndersiken. Rapamycine, in medisyn útbesocht by primaten, toande in beskieden libbensferlenjend effekt by mûzen, net by minsken. Metformine, in diabetesmiddel, korreleart mei in bytsje langer libjen yn guon ûndersiken, mar de kausaliteit bliuwt ûndúdlik. De bêst stipe maatregels binne ûnspektakulêr: regelmjittige beweging, acht oeren sliep, net smookje, sosjale kontakten ûnderhâlde.
De ynteresse fan miljardêrs yn ferâlderingsûndersyk is gjin leafdiedichheid. Dizze manlju wolle oan 'e dea ûntkomme. Dy fokus behearsket it hiele fakgebiet. Risikokapitaal jeit nei revolúsjonêre claims oer lang libjen, net nei maatregels dy't fergees binne of goedkeap. In ûndersyk dat oantoant dat deistich 30 minuten rinnen de stjerfte mei 15 prosint ferleget, lûkt gjin 100 miljoen dollar finansiering. In startup dy't sellulêre ûnstjerlikheid belooft, wol.
Epidemiologen dogge it earlike wurk yn ferâlderingsûndersyk, minsken by miljoenen folgend. Laboratoaria jeie sellulêre ûnstjerlikheid nei yn plak dêrfan. Mar dat wurk leveret gjin risikokapitaalrendimint op en makket gjin miljardêr ryk. Dêrom bliuwt it ûnderfinansjierd en sûnder wurdearring. De wierlike foarútgong fan it fakgebiet is reëel mar stadich. It ynvestearringslandskip stiet lykwols los fan de werklikheid.
Longevity startups raised $4.7 billion in 2024 and 2025, according to Crunchbase. Human lifespan in developed nations has not increased since the late 1990s. The gap between investment and outcome is growing wider.
The money flows from predictable sources: Bezos, Sam Altman, Peter Thiel. Venture capitalists follow. The narrative is seductive. One company, Altos Labs, raised $3 billion on the theory that reprogramming cells could reverse aging. Another, Calico, has spent $1.5 billion since 2013 with no approved drug on the market. Yet the hype machine drums on, undeterred by results.
The science itself is more modest. Most findings in mice do not replicate in humans. Caloric restriction extends lifespan in rodents but shows no clear human benefit across large studies. Rapamycin, a drug tested in primates, showed a modest lifespan extension in mice, not humans. Metformin, a diabetes drug, correlates with slightly longer life in some studies, but causation remains unclear. The best-supported interventions are unglamorous: regular exercise, eight hours of sleep, not smoking, maintaining social ties.
Billionaire interest in aging research is not charitable curiosity. These men want to escape death. That focus shapes the entire field. Venture money chases longevity claims that sound revolutionary, not interventions that are free or cheap. A study showing that walking for 30 minutes daily reduces mortality by 15 percent does not attract $100 million in funding. A startup promising cellular immortality does.
Epidemiologists do the honest work in longevity research, tracking millions of people. Labs chase cellular immortality instead. But that work pays no venture returns and makes no billionaire rich. So it remains underfunded and under-hyped. The field's actual progress is real but slow. The investment landscape, however, remains divorced from reality.
Published August 2, 2026 · Frisian News · Ljouwert, Fryslân